| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CCLE | pan-cancer | AAC | -0.11 | 0.01 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | -0.091 | 0.01 |
| mRNA | Erlotinib | UHNBreast | pan-cancer | AAC | -0.65 | 0.01 |
| mRNA | BRD8899 | CTRPv2 | pan-cancer | AAC | 0.095 | 0.01 |
| mRNA | NSC95397 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.01 |
| mRNA | BIRB 0796 | GDSC1000 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | fluvastatin | CTRPv2 | pan-cancer | AAC | 0.092 | 0.01 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | decitabine:carboplatin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.071 | 0.01 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.083 | 0.02 |